ATI INC. DL-,01/ US01741R1023 /
6/12/2024 10:35:09 AM | Chg. -0.400 | Volume | Bid10:00:01 PM | Ask10:00:01 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
53.540EUR | -0.74% | 0 Turnover: 0.000 |
-Bid Size: - | -Ask Size: - | 6.76 bill.EUR | - | - |
GlobeNewswire
6/12
Tri Pointe Homes Promotes Linda Mamet to Executive Vice President and Names Urmila Menon as Chief In...
GlobeNewswire
6/11
Corporate Employers Accused of Increasing Risk Of Pension Shortfalls in Violation of Employee Retire...
GlobeNewswire
5/30
Corporate Employers Accused of Increasing Risk Of Pension Shortfalls in Violation of Employee Retire...
GlobeNewswire
5/23
Corporate Employers Accused of Increasing Risk Of Pension Shortfalls in Violation of Employee Retire...
GlobeNewswire
5/21
Acoustic Technology, Inc. (ATI Systems) Revolutionizes Emergency Communication with Unique Advanced ...
GlobeNewswire
5/7
Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update
GlobeNewswire
3/27
William & Mary Campus Mass Notification Drill Using ATI Systems’ Mass Notification Solution
GlobeNewswire
3/12
Researchers Publish Manuscript on the Prevention and Emergency Response to Tularemia Outbreaks
GlobeNewswire
2/13
Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2024
GlobeNewswire
2/6
Seoul Robotics to Pursue Initial Public Offering with Samsung Securities as it Expands OEM Partnersh...
GlobeNewswire
12/27/2023
Eco Bright Future, Inc. Announces Signing of "Letter-of-Intent" With United Heritage, Sociedad Anoni...
GlobeNewswire
12/12/2023
Astrotech Announces Exciting New Technology Application and Introduces New Subsidiary
GlobeNewswire
11/13/2023
Aclaris Therapeutics Announces Top-line Results from 12-Week Phase 2b Trial of Oral Zunsemetinib (AT...
GlobeNewswire
11/6/2023
Aclaris Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Corporate Update
GlobeNewswire
10/27/2023
Strategic Advisory Board Elevates sureti’s Property Claims Resolution Capabilities
GlobeNewswire
10/25/2023
Excision BioTherapeutics Presents Positive Interim Clinical Data from Ongoing Phase 1/2 Trial of EBT...